PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: COMBINATION_PRODUCT: JS001 120mg+GP|COMBINATION_PRODUCT: JS001 240mg+GP|COMBINATION_PRODUCT: JS001 480mg+GP|COMBINATION_PRODUCT: GP followed by JS001
Sponsor: Fudan University